Core Viewpoint - The lawsuit involving Changcheng Securities is a historical issue from over 20 years ago, focusing on the confirmation of shareholder identity due to the company's operational suspension and revocation of its business license, making the valuation of its equity uncertain [1][5]. Group 1: Lawsuit Details - On September 16, Changcheng Securities announced a court hearing for a "shareholder qualification confirmation dispute" against Shenzhen Sanjiu Weitai Co., Ltd., with a hearing scheduled for November 7 [2]. - Changcheng Securities is seeking confirmation of its ownership of 900,000 shares in Sanjiu Weitai and requests the issuance of share certificates and registration in the shareholder registry [2]. Group 2: Background of Sanjiu Weitai - Sanjiu Weitai Co., established in 1993, was a chemical pharmaceutical raw material manufacturer that had its business license revoked in 2022 and is now considered a "zombie enterprise" [4]. - The company was once part of the well-known "999" brand, which has since been absorbed by China Resources Group during a restructuring process due to financial difficulties [10][11]. Group 3: Historical Context and Financial Implications - In 2008 and 2009, Changcheng Securities attempted to sell shares in 12 companies, including the 900,000 shares of Sanjiu Weitai, with the initial listing price dropping from 30,285,700 yuan to 24,228,600 yuan [7]. - The ongoing legal actions are part of a broader effort to resolve historical issues related to equity ownership, which arose during the transfer of shares by original shareholders between 2000 and 2008 [8]. Group 4: Legal and Financial Strategy - Legal experts suggest that the lawsuit serves multiple purposes: confirming shareholder identity, facilitating the appointment of a liquidation team, and ensuring rights to any remaining assets post-liquidation [8]. - For Changcheng Securities, which has total assets exceeding 100 billion yuan, resolving these historical equity issues is more about clarifying asset ownership than financial gain from the "zombie enterprise" [9].

Core Viewpoint - Changcheng Securities has initiated a lawsuit against Sanjiu Weitai Co., Ltd. to confirm its shareholder status and seek the issuance of share certificates for its 900,000 shares, as the company has been dissolved and is no longer operational [1][2]. Group 1: Company Background - Sanjiu Weitai Co., Ltd. was established in 1993 and was a manufacturer of chemical pharmaceutical raw materials, but its business license was revoked in 2022 [2]. - The company was once associated with the well-known "999" brand, which was part of the Shenzhen Southern Pharmaceutical Factory, now a residential area [2][6]. - The original Sanjiu Group, founded in 1991, expanded significantly but faced liquidity crises leading to restructuring by China Resources Group in 2007 [6][7]. Group 2: Legal Proceedings - The lawsuit is part of a historical issue dating back over 20 years, aimed at clarifying the ownership of assets and ensuring compliance as a listed company [5]. - Changcheng Securities has previously attempted to divest its shares in Sanjiu Weitai, with the shares listed for sale at a significantly reduced price in 2008 [3][4]. - The legal action may also facilitate the appointment of a liquidation team for Sanjiu Weitai, as it has not undergone liquidation since its license was revoked [4]. Group 3: Industry Context - The broader context involves the ongoing cleanup of "zombie enterprises" by state-owned enterprises, with efforts to clear out non-core and inefficient assets [7]. - China Resources Group has been actively pursuing the liquidation of former subsidiaries of the Sanjiu Group, with over 20 forced liquidation cases filed recently [7][8].

本次股票发行后拟在创业板市场上市，该市场具有较高的投资风险。创业板公司具 有创新投入大、新旧产业融合成功与否存在不确定性、尚处于成长期、经营风险高、业 绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资者应充分了解创业板 市场的投资风险及本公司所披露的风险因素，审慎作出投资决定。 湖北省宏源药业科技股份有限公司 Hubei Hongyuan Pharmaceutical Technology Co., Ltd. （湖北省罗田县凤山镇经济开发区宏源路 8 号） 首次公开发行股票并在创业板上市 招股说明书 保荐人（主承销商） （中国（上海）自由贸易试验区浦明路 8 号） 湖北省宏源药业科技股份有限公司 招股说明书 | 发行股票类型： | 人民币普通股（A 股） | | | | | --- | --- | --- | --- | --- | | 发行股数： | 本次股票的发行总量为 股本的比例为 | | | 4,725.72 万股，占公司发行后总 11.81%；本次发行公司原股东不公开发售 | | | 股份 | | | | | 每股面值： | 人民币 元 | | 1.00 | | | 每股发行价格： | 人 ...

安徽峆一药业股份有限公司 安徽省天长市杨村工业区 安徽峆一药业股份有限公司招股说明书（申报稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律 效力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主 临较大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 保荐机构（主承销商） （安徽省合肥市梅山路 18 号） 联席主承销商 （中国（四川）自由贸易试验区成都市高新区交子大道 177 号中 海国际中心 B 座 17 楼） 1-1-0 证券简称： 峆一药业 证券代码： 430478 要服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票 ...

证券简称： 峆一药业 证券代码： 430478 安徽峆一药业股份有限公司 安徽省天长市杨村工业区 安徽峆一药业股份有限公司招股说明书（申报稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律 效力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主 要服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面 临较大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 保荐机构（主承销商） （安徽省合肥市梅山路 18 号） 联席主承销商 （中国（四川）自由贸易试验区成都市高新区交子大道 177 号中 1-1-0 海国际中心 B 座 17 楼） 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票 ...

本次股票发行后拟在创业板市场上市，该市场具有较高的投资风险。创业板公司具 有创新投入大、新旧产业融合成功与否存在不确定性、尚处于成长期、经营风险高、业 绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资者应充分了解创业板 市场的投资风险及本公司所披露的风险因素，审慎作出投资决定。 湖北省宏源药业科技股份有限公司 Hubei Hongyuan Pharmaceutical Technology Co., Ltd. （湖北省罗田县凤山镇经济开发区宏源路 8 号） 首次公开发行股票并在创业板上市 招股说明书 （注册稿） 本公司的发行申请尚需经深圳证券交易所和中国证监会履行相应程序。本招股说 明书（注册稿）不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当以 正式公告的招股说明书全文作为作出投资决定的依据。 保荐人（主承销商） （中国（上海）自由贸易试验区浦明路 8 号） 湖北省宏源药业科技股份有限公司 招股说明书（注册稿） | 发行股票类型： | 人民币普通股（A 股） | | --- | --- | | 发行股数： | 本次股票的发行总量不超过 4,725.72 万股，占公司发行 | | | 后总 ...